Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA3 | P07451 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16252942 | 0.79 | LMNA (0.37) | LMNACA12CA1CA2CA3 | |
| SCHEMBL10001843 | 0.79 | LMNA (0.37) | LMNACA12CA1CA2CA3 | |
| SCHEMBL19075243 | 0.76 | LMNA (0.30) | LMNACA12CA1CA2CA3 | |
| SCHEMBL8261417 | 0.76 | LMNA (0.42) | LMNACA12CA1CA2CA3 | |
| SCHEMBL101562 | 0.74 | PIK3CD (0.32) | — | |
| SCHEMBL6923986 | 0.73 | — | — | |
| SCHEMBL10074140 | 0.72 | LMNA (0.32) | LMNACA12CA1CA2CA3 | |
| SCHEMBL8259691 | 0.70 | LMNA (0.41) | LMNACA12CA1CA2CA3 | |
| SCHEMBL22078015 | 0.70 | LMNA (0.34) | LMNACA12CA1CA2CA3 | |
| SCHEMBL27339574 | 0.69 | LMNA (0.36) | LMNACA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020115555-A2 | CRF1 RECEPTOR ANTAGONIST, PHARMACEUTICAL FORMULATIONS AND SOLID FORMS THEREOF FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | NEUROCRINE BIOSCIENCES, INC. (US) | 2020-06-11 | — | — | WO | disclosed |